about
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokineticsHuman antibody production in transgenic animalsHigh-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH regionEffects of IgG and its F(ab')2 fragments of some patients with idiopathic thrombocytopenic purpura on platelet aggregation.Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.Humanization and characterization of an anti-human TNF-α murine monoclonal antibody.Overview on the use of therapeutic antibodies in drug discovery.Co-transplantation of human hematopoietic stem cells and human breast cancer cells in NSG mice: a novel approach to generate tumor cell specific human antibodies.Humanization and characterization of an anti-ricin neutralization monoclonal antibodyReprogramming the immune system.Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis.Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogeneCAMPATH: from concept to clinic.Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins.Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growthHumanized antibodies for antiviral therapyAntibody engineering to develop new antirheumatic therapies.Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer.Humanization of chimeric anti-CD20 antibody by logical and bioinformatics approach with retention of biological activity.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.Antibodies generated from human immunoglobulin miniloci in transgenic mice.Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins.Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic targetConcepts of antibody-mediated cancer therapy.Engineering a high-affinity humanized anti-CD24 antibody to target hepatocellular carcinoma by a novel CDR grafting design.Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage siteReshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo.Characterization of the three immunoglobulin G subclasses of macaques.Therapeutic antibodies: magic bullets hit the target.Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy.
P2860
Q24561800-8D0E4ED9-5962-48CB-9631-9E6D9F73A7C6Q27023477-C1B50FFC-7AE5-448A-8C82-A2AA3C107C74Q28709119-1013772D-58D3-423E-843A-A9A10C4DC59CQ33369865-3E5097C2-573D-454D-BAAE-BC903AEB7EBEQ33690437-55787AA7-BA6B-49D6-AF33-5B8B1CA9FF02Q33815758-CDE3BF44-E93B-43E0-8E97-D58BBEFD1CD1Q34147273-98057577-F389-4BB4-88C5-694A752CFAB8Q34223991-3C161691-214E-475E-940B-5625A6C32A53Q34438229-8DC1E63E-CD69-4EEF-BA07-972ED4004464Q34792489-F5473E1B-D0D3-482A-8347-8C242F2E553EQ36180692-CA248175-BC2D-4747-8986-934E92E97C94Q36230784-933BFB6C-3A3D-4CA8-B39D-95C8A6ADEC62Q36251298-97524B0B-1723-4377-9116-DA20C39989ECQ36269608-8CEAD019-FB7E-4C67-A433-CBE9A9F4FB24Q36710927-17F30D34-21F7-4FB9-BF0E-E9B588FF0D37Q37005563-B498CDA0-4426-435C-805C-8C6ADF67C633Q37466235-EA0CA990-0652-4A22-AB6F-F2A83C8EBA80Q37505420-FDC75E91-96C8-4BED-8E8A-B5BC89745802Q38337393-65DC857F-2443-489A-87E2-A94F3F59D074Q38735872-E349874E-2745-42C8-B365-9746D473D44EQ38916529-2DC34C51-4B86-49A9-9E3B-E7714371CDEEQ40150431-66B5AEB4-8B1C-4874-BCD5-FEE8688BC357Q40399353-D3776942-D4AD-45C7-BDF3-6B8BE9A443F1Q40510230-4AD15988-043A-46B9-B3A8-86504CF8DE1FQ40672537-3C7111F0-550D-4194-99B8-455FD6861604Q40865882-B3839B1A-894A-446A-834B-58B971C8EAA8Q40891323-A09193F0-6EA5-49E9-B2CA-4783F6495415Q41612710-3AF917B8-95EE-4E1A-AD29-91E1A982C055Q42390355-7DA927AB-21BD-40ED-A768-662ED5F9B49EQ42728565-B6A1B6A5-E7E0-4847-9EA6-9BF89B294ECCQ45874080-60578555-9023-4AA4-B267-43301368F330Q47959086-71984577-617E-4077-92C1-2A2BD4D4B18AQ48362690-9D6FCA8A-13D2-4EE4-9D91-4FFDC78729A1Q55554478-82B68911-E3DD-426E-ACE5-1E454717D687
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
The immunogenicity of chimeric antibodies
@ast
The immunogenicity of chimeric antibodies
@en
type
label
The immunogenicity of chimeric antibodies
@ast
The immunogenicity of chimeric antibodies
@en
prefLabel
The immunogenicity of chimeric antibodies
@ast
The immunogenicity of chimeric antibodies
@en
P2093
P2860
P356
P1476
The immunogenicity of chimeric antibodies
@en
P2093
Brüggemann M
Neuberger MS
P2860
P304
P356
10.1084/JEM.170.6.2153
P407
P577
1989-12-01T00:00:00Z